# Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

> **NCT06829823** · PHASE2 · NOT_YET_RECRUITING · sponsor: **ImmunityBio, Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Non-muscle Invasive Bladder Cancer (NMIBC)

## Interventions

- **DRUG:** N-803 and BCG
- **DRUG:** N-803 and Gemcitabine

## Key facts

- **NCT ID:** NCT06829823
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11
- **Primary completion:** 2026-11
- **Final completion:** 2029-11
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06829823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06829823, "Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06829823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*